Supplementary Dataset S1 from Comparison of Shared Class I HLA-Bound Noncanonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma
Proteogenomics leverages mass spectrometry (MS)-based proteomics data alongside genomics and transcriptomics data to identify neoantigens—unique peptide sequences arising from tumor-specific mutations
The ATLAS bioassay was developed to empirically identify neoantigens by expressing each unique patient-specific tumor mutation individually in E. coli, pulsing autologous dendritic cells in an ordered
Structure of 2Q1-Fab, an antibody selective for IDH2R140Q-HLA-B*07:02 Descriptor: 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, CHLORIDE ION, DI(HYDROXYETHYL)ETHER, ... Authors: Mi
Patient-specific (unique) tumour antigens, encoded by somatically mutated cancer genes, generate neoepitopes that are implicated in the induction of tumour-controlling T cell responses. We undertook t
Background: Messenger ribonucleic acid (mRNA) vaccine has been considered as a potential therapeutic strategy and the next research hotspot, but their efficacy against prostate adenocarcinoma (PRAD) r